Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

May 13, 2022

Study Completion Date

July 31, 2023

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

nab-Paclitaxel + Cisplatin + Gemcitabine

"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."

Trial Locations (4)

33136

University of Miami, Miami

53226

Froedtert & Medical College of Wisconsin, Milwaukee

70121

Ochsner Clinic Foundation, New Orleans

85258

HonorHealth Research Institute, Scottsdale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

HonorHealth Research Institute

OTHER